Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Iclusig“
Suchtreffer
Begriffe & Kennungen
Iclusig · 4.8 · 22 System organ class Frequency Adverse reactions Chills Influenza like illness Common Non-cardiac chest pain
Eintrag öffnenIclusig · 4.8 · 23 Ponatinib in combination with reduced- System Organ Class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 24 Ponatinib in combination with reduced- System Organ Class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 25 vascular arterial occlusive events was 473, 356, and 108 days, respectively in the OPTIC trial. Of the 94 p
Eintrag öffnenIclusig · 4.8 · 26 Table 11 Incidence of clinically relevant grade 3/4* laboratory abnormalities in ≥ 2% of patients in any di
Eintrag öffnenIclusig · 4.8 · 57 Patients with newly diagnosed Ph+ ALL (PhALLCON Study) Myelosuppression events were reported in 83 % of pon
Eintrag öffnenIclusig · 4.8 · 58 System organ class Frequency Adverse reactions Decreased appetite Very common Hypertriglyceridaemia Hyperch
Eintrag öffnenIclusig · 4.8 · 59 System organ class Frequency Adverse reactions Cardiac failure Myocardial infarction Cardiac failure conges
Eintrag öffnenIclusig · 4.8 · 60 System organ class Frequency Adverse reactions Dyspnoea Very common Cough Pulmonary embolism Pleural effusi
Eintrag öffnenIclusig · 4.8 · 61 System organ class Frequency Adverse reactions Rash pruritic Exfoliative rash Erythema Alopecia Skin exfoli
Eintrag öffnenIclusig · 4.8 · 62 System organ class Frequency Adverse reactions Chills Influenza like illness Common Non-cardiac chest pain
Eintrag öffnenIclusig · 4.8 · 63 Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 64 Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 65 vascular arterial occlusive events was 473, 356, and 108 days, respectively in the OPTIC trial. Of the 94 p
Eintrag öffnenIclusig · 4.8 · 66 Table 8 Incidence of clinically relevant grade 3/4* laboratory abnormalities in ≥ 2% of patients in any dis
Eintrag öffnenIclusig · 4.8 · After a minimum follow-up of 64 months, the rates of adverse reactions resulting in discontinuation were 20% i
Eintrag öffnenIclusig · 4.8 · After a minimum follow-up of 64 months, the rates of adverse reactions resulting in discontinuation were 20% i
Eintrag öffnenIclusig · 4.8 · Arterial cardiovascular, cerebrovascular, and peripheral vascular occlusive adverse reactions (treatment-emerg
Eintrag öffnenIclusig · 4.8 · Arterial cardiovascular, cerebrovascular, and peripheral vascular occlusive adverse reactions (treatment-emerg
Eintrag öffnenIclusig · 4.8 · Common Conjunctival hemorrhage Eye disorders Uncommon Retinal vein occlusion
Eintrag öffnen